Moreover, the complex interplay between PRMT dysregulation, particularly in PRMT5, and MTAP loss in NSCLC underscores the need for extensive research, validating the pursuit of PRMT5 and MAT2A inhibitors as promising therapeutic avenues. The gene discussed is MTAP; the disease is non-small cell lung carcinoma.